Medicare's $50 Obesity Drug Coverage Starts Wednesday, but 82% of Eligible Seniors Don't Know It Exists

Since Congress and the administration cleared the legal path for Medicare to cover obesity drugs, the policy debate has shifted to a more practical problem: getting the word out.

Starting Wednesday, eligible Medicare beneficiaries can receive GLP-1 obesity drugs — the blockbuster treatments from Novo Nordisk and Eli Lilly — through Medicare's new Bridge demonstration program for a monthly copay of $50. The program was originally announced for 2026 and has since been extended through 2027, according to CNBC.

The awareness gap is significant

A survey released in early June by the Obesity Care Advocacy Network found that 82% of Americans age 65 and older do not know Medicare is about to cover obesity drugs. The numbers are bipartisan: 79% of Republicans and 84% of Democrats in the same age group reported being unaware. The survey was conducted in late March among more than 2,100 adults 65 and older.

That is a wide informational gap for a benefit set to go live in days.

Why CMS has been quiet

The Centers for Medicare & Medicaid Services offered a rationale. A CMS official told reporters Thursday that the agency has done limited public outreach because beneficiaries are "most moved to take action" when a benefit is actually available to them. The official added that CMS will ramp up promotion after the July 1 launch, citing stewardship of taxpayer dollars.

Other experts told CNBC the quieter approach may also reflect practical logistics: making sure providers and pharmacies are operationally prepared before a flood of patients starts asking questions.

Those are defensible explanations. Launching a marketing blitz before the system can handle claims would create a different kind of problem.

The strongest counterargument

Skeptics of aggressive CMS outreach have a point worth taking seriously. A slower rollout could give physicians, pharmacies, and CMS time to prepare before a potentially large number of beneficiaries begin seeking treatment. Critics of broad GLP-1 expansion have argued that a demonstration program by definition should proceed methodically before scaling.

The coverage extension through 2027 suggests the administration already decided this program is here to stay, making the awareness gap less a feature and more a logistical failure to solve.

Getting covered is not simple

Even seniors who do know about the Bridge program face a multi-step process. Unlike standard Medicare drug benefits, enrollment is not automatic. Patients must meet eligibility requirements, get a prescription from a physician, and receive prior authorization approval through CMS before any coverage activates.

Dr. Shauna Levy, medical director of the Tulane Bariatric and Weight Loss Center, was direct about the likely outcome. "I have not seen a lot of information out there for the public, and I think there are going to be plenty of people who have zero knowledge of the Bridge program," she told CNBC. "And I think for patients, it's just going to take even longer for them to find out about it, and then see if they're eligible."

That delay matters medically. Obesity drives cardiovascular disease, diabetes, and joint deterioration. These conditions dominate Medicare spending. Every month an eligible patient doesn't know coverage exists is a month of continued risk and untreated disease.

Pharma's silence is notable

Novo Nordisk and Eli Lilly have historically spent aggressively on consumer advertising — television, subway ads, direct-to-consumer campaigns. Novo spent nearly $500 million on U.S. advertising for Wegovy and Ozempic in the first nine months of 2025, more than double the just over $200 million Lilly spent promoting Zepbound and Mounjaro, according to Reuters, citing data from ad-tracking firm MediaRadar. Yet neither company appears to have mounted a significant public outreach effort around the Bridge program's launch, according to CNBC. Physicians and experts interviewed said they noticed the absence.

Novo's Jamey Millar, executive vice president of U.S. operations, acknowledged there are no linear TV ads promoting the new coverage, but said awareness among patients will come from providers and pharmacies. Lilly's Ilya Yuffa, president of Lilly USA and global customer capabilities, said the company's approach is to ensure physicians are prepared before pursuing broad consumer awareness. Kenneth Thorpe, health policy professor at Emory University, said "getting the word out" about the program and who is eligible will likely be among the largest challenges of the rollout.

What happens next

CMS said it will increase promotional activity after July 1. How much, through which channels, and with what budget has not been specified publicly. The unresolved question going into the launch is whether the post-July-1 outreach arrives fast enough to prevent a situation where an eligible 70-year-old with obesity and prediabetes waits months simply because no one told them they qualified.